Cargando…

Prospective performance of the Prostate Health Index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4–10 ng/mL and negative digital rectal examination

BACKGROUND: The disadvantage of using total serum prostatic specific antigen (PSA) test for detection of prostate cancer is that it has a low specificity. The low specificity of total PSA (tPSA) test leads to unnecessary prostate biopsies. In this prospective study, we assessed the serum tPSA, free...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sriplakich, Supon, Lojanapiwat, Bannakij, Chongruksut, Wilaiwan, Phuriyaphan, Siwat, Kitirattakarn, Pruit, Jun-Ou, Jakrit, Amantakul, Akara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Pacific Prostate Society 2018
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251939/ https://www.ncbi.nlm.nih.gov/pubmed/30505815 http://dx.doi.org/10.1016/j.prnil.2018.02.002

Ejemplares similares

Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice
por: Lojanapiwat, Bannakij, et al.
Publicado: (2014)

Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration‐resistant prostate cancer: Real‐world experience in the Southeast Asian cohort
por: Lim, Jasmine, et al.
Publicado: (2020)

Guy's Stone Score (GSS) Based on Intravenous Pyelogram (IVP) Findings Predicting Upper Pole Access Percutaneous Nephrolithotomy (PCNL) Outcomes
por: Lojanapiwat, Bannakij, et al.
Publicado: (2016)

Optimizing surgical outcomes in bladder cancer patients undergoing radical cystectomy
por: Pere, Maria, et al.
Publicado: (2023)

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand
por: Lojanapiwat, Bannakij, et al.
Publicado: (2017)

Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?
por: Koc, Gokhan, et al.
Publicado: (2017)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
por: Fiamegos, Alexandros, et al.
Publicado: (2016)

Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

Is targeted biopsy really needed when performing systematic prostate biopsy to raise the detection rate for prostate cancer in patients with prostate-specific antigen ≤10 ng/mL?
por: Park, Jee Soo, et al.
Publicado: (2019)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(−1)
por: Chen, Rui, et al.
Publicado: (2015)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng ml(−1)
por: Tan, Lincoln GL, et al.
Publicado: (2017)

Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis
por: Kan, Hung-Cheng, et al.
Publicado: (2017)

Comparison of prostate cancer detection rates of various prostate biopsy methods for patients with prostate-specific antigen levels of <10.0 ng/mL in real-world practice
por: Oh, Kyung Tak, et al.
Publicado: (2020)

Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination
por: Chiu, Peter Ka-Fung, et al.
Publicado: (2016)

Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL
por: Ahn, Jae Hyun, et al.
Publicado: (2014)

The efficacy of peritubal analgesic infiltration in postoperative pain following percutaneous nephrolithotomy – A prospective randomized controlled study
por: Lojanapiwat, Bannakij, et al.
Publicado: (2015)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
por: Iwamoto, Hiroaki, et al.
Publicado: (2019)

Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score
por: Fang, Dong, et al.
Publicado: (2015)

Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease?
por: Taverna, Gianluigi, et al.
Publicado: (2012)

Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml
por: Wang, Xuan, et al.
Publicado: (2016)

Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL
por: Lee, Dong Hoon, et al.
Publicado: (2016)

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml
por: Ferro, Matteo, et al.
Publicado: (2013)

Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml(−1) to 10 ng ml(−1)
por: Zhang, Chi-Chen, et al.
Publicado: (2022)

Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL)
por: Chung, Jae Hoon, et al.
Publicado: (2020)

AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
por: Fang, Dong, et al.
Publicado: (2016)

Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL
por: Zhou, Yongqiang, et al.
Publicado: (2017)

Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy
por: Wu, Qiang, et al.
Publicado: (2021)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA
por: Zhao, Jing, et al.
Publicado: (2016)

Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
por: Su, Rui, et al.
Publicado: (2022)

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
por: Lee, Seung Hwan, et al.
Publicado: (2011)

The Diagnostic Values of Pretreatment Serum Inflammation Markers and Lipoprotein in Men With Total Prostate-Specific Antigen Between 4 and 10 ng/ml
por: Li, Guangping, et al.
Publicado: (2020)

Impact of Real-Time Elastography versus Systematic Prostate Biopsy Method on Cancer Detection Rate in Men with a Serum Prostate-Specific Antigen between 2.5 and 10 ng/mL
por: Taverna, Gianluigi, et al.
Publicado: (2013)

Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0–10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium
por: Chen, Rui, et al.
Publicado: (2015)

Efficacy of Repeated Transrectal Prostate Biopsy in Men Younger Than 50 Years With an Elevated Prostate-Specific Antigen Concentration (>3.0 ng/mL): Risks and Benefits Based on Biopsy Results and Follow-up Status
por: Park, Ho Gyun, et al.
Publicado: (2014)

Prostate Cancer Can Be Detected Even in Patients with Decreased PSA Less than 2.5 ng/ml after Treatment of Chronic Prostatitis
por: Kim, Young Jung, et al.
Publicado: (2011)

Diagnostic Accuracy of Prebiopsy Ga-68 PSMA PET/CT in Detecting Primary Prostate Carcinomas with Prostate-Specific Antigen <50 ng/ml
por: Chandra, Piyush, et al.
Publicado: (2020)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml(−1))
por: Liu, Jun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m9o00jcf75uob7ckft5dinhe91